A
AFYX Therapeutics
Private biopharmaceutical company providing targeted drug delivery for mucosal diseases
About AFYX Therapeutics
AFYX Therapeutics is a pioneering healthcare startup specializing in the development of innovative mucoadhesive patches for the treatment of mucosal diseases. The company focuses on creating topical patches that adhere to mucosal surfaces, such as the oral cavity and vulvar area, to deliver medication directly to the affected site. This targeted approach aims to improve treatment efficacy while minimizing side effects.
AFYX Therapeutics primarily serves patients suffering from conditions like Vulvar Lichen Sclerosus and oral mucosal diseases. These conditions often require localized treatment, which AFYX's patches are designed to provide. The company operates in the biopharmaceutical market, specifically within the niche of mucosal drug delivery systems.
The business model of AFYX Therapeutics revolves around research and development (R&D) of these specialized patches, followed by clinical trials to ensure their safety and effectiveness. Once the products are proven effective, the company seeks regulatory approval to bring them to market. AFYX makes money by securing funding through convertible loans and investments, as well as through potential future sales of their approved products.
AFYX Therapeutics has already made significant strides, including closing a $13 million convertible loan financing and submitting Investigational New Drug (IND) and Clinical Trial Application (CTA) for Phase 2B studies. The company collaborates with renowned experts and institutions in dermatology and oral health to validate their products.
In summary, AFYX Therapeutics is dedicated to improving the lives of patients with mucosal diseases through innovative, targeted drug delivery systems. Their focus on R&D, clinical validation, and strategic partnerships positions them well in the biopharmaceutical market.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Employees
- 12
- Open positions
- None listed
- Dealroom signal
- 92.0/100
- Industry
- Health
- Sub-industry
- Pharmaceutical, BioTechnology
- Sector
- Biotechnology, Biotech and Pharma, Hard Tech, Horizon Europe, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- B2B
News
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| CONVERTIBLE✓Equity / VC | Jun 2019 | $13M | — | Sofinnova Investments · Novo Seeds · Lundbeckfonden Emerge | — |
| SERIES A✓Equity / VC | May 2017 | $18M | $71M | Lundbeckfonden Emerge · Novo Seeds · Sofinnova Investments | ↗ |
Growth signals
Latest recorded traffic for AFYX Therapeutics is 520 monthly website visits, up 73.3% over the last three months. AFYX Therapeutics's team grew 0% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
AFYX Therapeutics in the Copenhagen ecosystem
The AFYX Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A3 investors entered at this stage
Lundbeckfonden Emerge
Novo Seeds
Sofinnova Investments
Other known investors2 additional known investors
Lundbeckfonden
Novo Holdings
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about AFYX Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See AFYX Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.









